CN103142909B - Orally traditional Chinese medicine composition for treating lung cancers - Google Patents
Orally traditional Chinese medicine composition for treating lung cancers Download PDFInfo
- Publication number
- CN103142909B CN103142909B CN201310112691.XA CN201310112691A CN103142909B CN 103142909 B CN103142909 B CN 103142909B CN 201310112691 A CN201310112691 A CN 201310112691A CN 103142909 B CN103142909 B CN 103142909B
- Authority
- CN
- China
- Prior art keywords
- processed
- honey
- times amount
- radix
- extractum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, and particularly relates to an orally traditional Chinese medicine composition for treating lung cancers. The orally traditional Chinese medicine composition comprises radix stemonae baked with honey, baked radix asteris and raw tussilago farfara serving as active ingredients according to a given weight ratio, and the active ingredients can be directly prepared into oral dosage forms, and can also be prepared into oral solid preparations or oral liquid preparations by adding pharmaceutic adjuvant. The invention also provides a preparation method of the orally traditional Chinese medicine composition for treating lung cancers. The orally traditional Chinese medicine composition has an exact curative effect on lung cancers, has higher safety than that of cell toxicity chemotherapeutics and is beneficial to solving the problem of low survival rate caused by high toxicity of the cell toxicity chemotherapeutics.
Description
Technical field
The invention belongs to tcm field, be specifically related to a kind of oral Chinese medicine composition for the treatment of pulmonary carcinoma.
Background technology
Pulmonary carcinoma can be divided into small cell lung cancer and nonsmall-cell lung cancer two kinds, it is one of clinical modal malignant tumor, to occur and case fatality rate has accounted for the first place of global most big and medium-sized cities malignant tumor, and sickness rate in China with other many countries and regions still in continuous rising.Although can adopt the multiple therapy methods such as excision, chemotherapy, radiotherapy to pulmonary carcinoma at present, its 5 years survival rates are still in extremely low level.To add up according to foreign data. patients with lung cancer 5 years markization survival rates are only 8 ~ 14%, belong to late period, lose surgical engine meeting when the patients with lung cancer of nearly 65% is made a definite diagnosis, and have to seek help from the treatment of chemicals.For nonsmall-cell lung cancer, except minority pathological changes limitation, can accept outside radiotherapy or outside operative treatment, all the other Therapeutic Method are palliative therapy.Although have been reported in the world, chemotherapy can provide the absolute benefit of 6 ~ 7% to patients with advanced NSCLC.But still deposit dispute.
At present, for pulmonary carcinoma, desirable Therapeutic Method remains early discovery and excision pathological tissues as far as possible completely.In addition other therapies, as radiotherapy and chemotherapy all exist significant toxic action.The mechanism of radiotherapy and chemicals killer cell, usually by attacking human body cell, the cytotoxic effect blocking cellular replication expression carrys out killing tumor cell, or the biomacromolecule come as the various reactive oxygen free radical having a destruction to biomacromolecule by metabolite or metabolic by-product in collateral damage tumor cell, is played and kills or the effect of inhibition tumor cell propagation.
But, this lethal effect to cell, usual None-identified normal cell and tumor cell.Therefore, while killing tumor cell, to the cell tissue around the tumor tissue even cell tissue of whole body, can especially divide vigorous cell tissue, as bone marrow etc. produces unnecessary effect, thus bring out dose-dependent toxicity.Although if anthracycline antimicrobial antitumor drug is very effective broad-spectrum anti-cancer drug clinically, there is significant cardiac toxicity, have impact on its clinical practice, limit the performance of its therapeutical effect.This cardiac toxicity is considered to be caused by multiple factors, comprises the generation of free radical and the accumulation etc. of drug metabolite in the impact on Buddhist nun's alkali receptor blue on myocardial cell sarcoplasmic reticulum, heart.There is serious Toxicity of Kidney in metal platinum complex antitumor drug, another clinical effective broad-spectrum anti-cancer drug cyclophosphamide then exists inevitable genotoxicity, and high dose use can bring out the side effect such as heart disease and pulmonary fibrosis.
The numerous monomeric compound molecules extracted from Chinese crude drug have been proved to be has certain antitumor action, and e.g., matrine and curcumin have Developing restraint and and the effect of cell death inducing to Lung Adenocarcinoma A 549 Cell growth, lung adenocarcinoma cell.Colchicine mitosis capable of inhibiting cell, make nuclear structures deformity and dead, for breast carcinoma, skin carcinoma, esophageal carcinoma etc.Nearest research display, composition in Flos Farfarae is as 1,2-di-(3 ', 4 '-dihydroxycinnamoyl)-cychopenta-3-ol, Quercetin and isoquercitrin (Isoquercitrin) to lung carcinoma cell LA795 propagation there is certain inhibitory action (Liu Keyue, bang army, Wu Jiazhong, Zhang Tiejun. suppress the study of active components that lung carcinoma cell LA795 breeds in Flos Farfarae. " Fudan Journal: natural science edition " the 48th volume the 1st phase 125-129 page in 2009 .).
Also certain therapeutical effect has been played to tumor clinically according to Chinese medical book or some compound preparations through improving, as SHENMAI ZHUSHEYE, softening the hard mass fall apart.Chinese medicine is no matter in suppression or killing tumor cell or postoperative conditioning, alleviate Radiotherapy chemotherapy untoward reaction, improve sings and symptoms, improve the aspects such as life quality, all play certain effect, but except some classic prescriptions through Long-term clinical checking, experience prescription, other Chinese crude drug folk prescriptions or prescription not yet find to have significant antitumor action.Although some are separated the compound such as colchicine and the Quercetin that obtain from Chinese medicine have certain tumor-inhibiting action, after these compounds use, toxicity is very large, as colchicine have serious toxic action to kidney and hemopoietic system ill effect obvious; And now there are some researches show, Quercetin also has significant genetoxic, (ring flies, Cheng Jie, Jin Suxiang to demonstrate obvious mutagenicity to mammalian cell, Xu Juanhua, Wang Jun, Xiao Hang. Quercetin genetoxic research in mammalian cell in vitro. " Chinese preventive medicine magazine " the 8th phase 797-800 page in 2010 .), when being used as medicine with the form of overall medical material, then because the content of tumor suppression composition in medical material is lower, and the drug effect that single compound can reach cannot be reached.
Summary of the invention
For above-mentioned prior art, an object of the present invention is to provide a kind of pharmaceutical composition for the treatment of pulmonary carcinoma, treat an oral Chinese medicine composition for pulmonary carcinoma specifically, to overcome the large defect of toxic and side effects that traditional chemical Drug therapy causes and the low problem of survival rate.
For realizing above-mentioned object, the technical solution used in the present invention is:
Treat an oral Chinese medicine composition for pulmonary carcinoma, the effective ingredient of this oral Chinese medicine composition is made up of the raw material of following weight ratio:
The processed with honey Radix Stemonae 20 weight portion
Radix Asteris (processed with honey) 40 weight portion
Raw Flos Farfarae 40 weight portion.
The oral Chinese medicine composition of described treatment pulmonary carcinoma, directly makes the peroral dosage form of clinical acceptance.
The oral Chinese medicine composition of described treatment pulmonary carcinoma adds pharmaceutically acceptable carrier, makes the peroral dosage form of clinical acceptance.
Another aspect of the present invention additionally provides the preparation method of the oral Chinese medicine composition of above-mentioned treatment pulmonary carcinoma, and step is: ground by raw Flos Farfarae, cross 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2 ~ 4 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 5 ~ 8 times amount, and second time adds the decocting 1 ~ 3 hour of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 3 ~ 6 times amount; Collecting decoction, filter, filtrate being concentrated into relative density at 55 ~ 70 DEG C is the extractum of 1.20 ~ 1.30, mix homogeneously with above-mentioned powder, finally conveniently operation is directly or add pharmaceutically acceptable carrier and make arbitrary dosage form in the tablet of clinical acceptance, capsule, granule, oral liquid.
Further, above-mentioned method for preparing tablet thereof, step is: ground by raw Flos Farfarae, cross 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 6 times amount, and second time adds the soak by water 2 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 5 times amount; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.28; Mix homogeneously with above-mentioned powder, add the sodium carboxymethyl cellulose of extractum weight 0.5 times amount, the microcrystalline Cellulose of extractum weight 0.2 times amount, the lactose of extractum weight 0.5 times amount, mixing, 80% alcohol granulation, 45 DEG C of oven dry, after adding the magnesium stearate mixing of extractum weight 0.1 times amount, tabletting, both obtained tablet.
Further, the preparation method of above-mentioned capsule, step is: ground by raw Flos Farfarae, cross 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 3.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 7 times amount, and second time adds the soak by water 1.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 4 times amount; Collecting decoction, filter, filtrate being concentrated into relative density at 60 DEG C is the extractum of 1.24; Mix homogeneously with above-mentioned powder, dry, pulverize, cross 200 mesh sieves, add the Pulvis Talci of extractum weight 0.1 times amount, mix homogeneously, incapsulate and both obtained capsule.
Further, the preparation method of above-mentioned granule, step is: ground by raw Flos Farfarae, cross 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2.2 hours of 5.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 2.5 hours of 5.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.26; Mix homogeneously with above-mentioned powder, add the sweetener of extractum weight 2 times amount and the dextrin of extractum weight 0.01 times amount, spraying dry, be pressed into thin slice with the dry granulator that squeezes, then crushing and pelletizing both obtained granule.
Further, the preparation method of above-mentioned oral liquid, step is: ground by raw Flos Farfarae, cross 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 3 hours of 7.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 1.5 hours of 3.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.23; Mix homogeneously with above-mentioned powder, add distilled water diluting, add the Mel of extractum weight 0.1 ~ 0.5 times amount and the sucrose of extractum weight 0.5 ~ 1 times amount, boil, stirring and dissolving, filter while hot, antiseptic is added after cooling, add pH adjusting agent and PH value is adjusted to 4.2 ~ 6.3, use distilled water standardize solution, subpackage both obtained oral liquid.
In a preferred embodiment, described antiseptic is sorbic acid.
In a preferred embodiment, described pH adjusting agent is citric acid.
Radix Stemonae phonetic described in technical scheme of the present invention is called Baibu, English RADIX STEMONAE by name is the dried root of Stemonaceae plant Radix Stemonae [Stemona sessilifolia (Miq.) Miq.], Radix stemonae japonicae [Stemona japonica (Bl.) Miq.] or radix stemonae tuberosae [Stemona tuberosa Lour.].The source of the processed with honey Radix Stemonae, quality standard and preparation method, all on the books in Chinese Pharmacopoeia version in 2000 first, China's coastal port one.The source of the Radix Asteris (processed with honey) described in technical scheme of the present invention, quality standard and concocting method, be recorded in Chinese Pharmacopoeia version one in 1985.The raw medicinal herbs of the raw Flos Farfarae described in technical scheme of the present invention and Chinese crude drug Flos Farfarae, its source, quality standard and concocting method are all on the books in China's coastal port one, Chinese Pharmacopoeia version one in 2010.This is well known to those of ordinary skill in the art.
Technical solution of the present invention term used " pharmaceutically acceptable carrier " refers to that medicine is when preparation prescription designs, for solving the mouldability of preparation, the general designation of all carriers except principal agent that effectiveness, stability, safety add.They itself are not induced and produce the antibody harmful to the individuality accepting said composition, and do not produce obvious toxicity when not producing toxicity or life-time service to body after administration.These carriers are well known to those of ordinary skill in the art, as the excipient for promoting preparation formation specific modality; Regulate flavouring agent, the sweeting agent of preparation mouthfeel; Promote solid pharmaceutical preparation at the disintegrating agent of digestive tract disintegrate as carboxymethyl starch sodium, hyprolose, cross-linked carboxymethyl cellulose; Promote that the absorption enhancer of drug absorption is as quaternary ammonium compound; Promote that the lubricant of drug particles mobility is as Pulvis Talci, calcium stearate; That preparation forms the diluent of liquid form as water, glucose etc.
Term used " peroral dosage form of clinical acceptance " refers to the form being applicable to clinical oral administration that medicine is made by medicine, as tablet, capsule, pill, granule, oral administration solution, oral administration mixed suspension etc.These peroral dosage forms, have and are convenient to patient and carry the advantage with self-administration, and preparation method is simple, is the clinical common form of field of medicaments.These peroral dosage forms are well known to those of ordinary skill in the art, can obtain without the need to creative work.
The discovery that the present inventor is surprised in experimentation, by the compound preparation that Chinese medicine honey Radix Stemonae (processed), Radix Asteris (processed with honey) and raw Flos Farfarae form according to certain ratio, to pulmonary malignant tumour, has unexpected therapeutic effect.The tumor-inhibiting action produced is significantly higher than the tumour inhibiting rate of Flos Farfarae.Said composition has effective therapeutical effect to pulmonary carcinoma, pulmonary carcinoma is had to the effect extending the survival of patients phase, has good safety, and preparation process is simple, and cost is lower, is conducive to clinical practice.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further explained.Should be understood that, following examples only for explaining the present invention, instead of limit the scope of the invention.
Embodiment 1 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of preparation thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: by above-mentioned three kinds of medical materials mixing, be ground into powder, cross 20 ~ 200 mesh sieves, dry, then direct compression makes 7000 tablets of tablets, or average subpackage is as 7000 capsules, also can be distributed into moistureproof packaging bag, make 7000 bags of powders.
Embodiment 2 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of preparation thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: raw Flos Farfarae is ground, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 3 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 7 times amount, and second time adds the decocting 2 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 5 times amount; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.27, and mix homogeneously with above-mentioned powder, then direct compression makes 10000; Or average subpackage is as 10000 capsules; Or be distributed into moistureproof packaging bag, make 10000 bags of powders.
Embodiment 3 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of tablet thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: raw Flos Farfarae is ground, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water two
Secondary, first time adds the soak by water 2.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 6 times amount, and second time adds the soak by water 2 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 5 times amount; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.28; Mix homogeneously with above-mentioned powder, add the sodium carboxymethyl cellulose of extractum weight 0.5 times amount, the microcrystalline Cellulose of extractum weight 0.2 times amount, the lactose of extractum weight 0.5 times amount, mixing, 80% alcohol granulation, 45 DEG C of oven dry, after adding the magnesium stearate mixing of extractum weight 0.1 times amount, be pressed into 5000 tablets of tablets and both obtained.
Embodiment 4 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of capsule thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: raw Flos Farfarae is ground, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 3.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 7 times amount, and second time adds the soak by water 1.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 4 times amount; Collecting decoction, filter, filtrate being concentrated into relative density at 60 DEG C is the extractum of 1.24; Mix homogeneously with above-mentioned powder, dry, pulverize, cross 200 mesh sieves, add the Pulvis Talci of extractum weight 0.1 times amount, mix homogeneously, average mark loads 10000 seed lac softgel shells, both obtains capsule.
Embodiment 5 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of pill thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: the preparation method of described oral Chinese medicine composition, step is: ground by raw Flos Farfarae, cross 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2.5 hours of 6.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 2.5 hours of 6 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.25; Mix homogeneously with above-mentioned powder, add the refined honey of extractum weight 0.8 times amount, mix homogeneously, pill bar, gradation, round, make 2000 pills and both obtained.
Embodiment 6 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of granule thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: raw Flos Farfarae is ground, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2.2 hours of 5.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 2.5 hours of 5.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.26; Mix homogeneously with above-mentioned powder, add the sweetener of extractum weight 2 times amount and the dextrin of extractum weight 0.01 times amount, spraying dry, be pressed into thin slice with the dry granulator that squeezes, then crushing and pelletizing, be on average packed as 5000 parts, both obtain granule.
Embodiment 7 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of oral liquid thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: raw Flos Farfarae is ground, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water two
Secondary, first time adds the soak by water 3 hours of 7.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 1.5 hours of 3.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.23; Mix homogeneously with above-mentioned powder, add distilled water diluting, add the Mel of extractum weight 0.1 ~ 0.5 times amount and the sucrose of extractum weight 0.5 ~ 1 times amount, boil, stirring and dissolving, filter while hot, sorbic acid is added anticorrosion after cooling, add citric acid and PH value is adjusted to 4.2 ~ 6.3, use distilled water standardize solution, subpackage both obtained oral liquid.
Embodiment 8 treats the oral Chinese medicine composition of pulmonary carcinoma and the preparation of oral liquid thereof
Processed with honey Radix Stemonae 25kg
Radix Asteris (processed with honey) 50kg
Raw Flos Farfarae 50kg
Preparation: raw Flos Farfarae is ground, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water two
Secondary, first time adds the soak by water 3 hours of 7.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 1.5 hours of 3.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filter, filtrate being concentrated into relative density at 65 DEG C is the extractum of 1.23; Mix homogeneously with above-mentioned powder, add distilled water diluting, add the Mel of extractum weight 0.1 ~ 0.5 times amount and the sucrose of extractum weight 0.5 ~ 1 times amount, boil, stirring and dissolving, filter while hot, calcium propionate is added anticorrosion after cooling, add citric acid and PH value is adjusted to 4.2 ~ 6.3, use distilled water standardize solution, subpackage both obtained oral liquid.
Embodiment 9 treats the oral Chinese medicine composition of pulmonary carcinoma to pharmacodynamic experiment in the body of nonsmall-cell lung cancer
NIH mice, male, 18 ~ 22g, 50.A549 Lines is inoculated in the DMEM culture medium containing 10% calf serum, at 5 % CO at 37 DEG C
2cell culture incubator in cultivate, take the logarithm growth mid-term A549 cell, according to 1x10
7individual cell/nude inoculation sets up Transplanted tumor model in nude mice by subcutaneous, reaches after 4mm be divided into 5 groups at random until transplanted tumor average diameter, often organize 10 mices, A group as negative control group, feed standard mice full nutrition pellet; B group is administration group, and except normal feeding mice full nutrition pellet, evening every day, gavage gave oral liquid prepared by embodiment 7, and dosage is 50mg/kg, successive administration 60 days; C group is positive controls intraperitoneal injection of cyclophosphamide (0.5mg/kg), and evening every day is administered once, successive administration 60 days.D group is single medicinal material matched group, and except normal feeding mice full nutrition pellet, evening every day, gavage gave commercially available Stemona Root, and dosage is 50mg/kg, successive administration 60 days; E group is single medicinal material matched group, and except normal feeding mice full nutrition pellet, evening every day, gavage gave commercially available Common Coltsfoot Flower, and dosage is 50mg/kg, successive administration 60 days.Often group was in administration the 20th day, measured tumor volume, and calculate tumour inhibiting rate, computing formula is: (initial tumor volume-administration posterior tuberosity volume)/initial tumor volume (being expressed as a percentage).Often group calculates animal dis motility rate on the 60th day in administration.The results are shown in Table 1.
The tumour inhibiting rate of table 1 Chinese medicine composition oral liquid on nonsmall-cell lung cancer mice and the impact of survival rate
A: representative has significant difference (p < 0.05) compared with C group; B: representative has the difference (p < 0.01) of highly significant compared with C group; C: representative has significant difference (p < 0.05) compared with A group; D: representative has the difference (p < 0.01) of highly significant compared with A group
From table 1, the remarkable high negative control group of the tumour inhibiting rate of Chinese medicinal composition granules to nonsmall-cell lung cancer mice and single medicinal material matched group, and Chinese medicinal composition granules feeding mice is after 60 days, although tumour inhibiting rate and cyclophosphamide group there are differences, but mouse survival rate is significantly higher than cyclophosphamide group, prompting Chinese medicinal composition granules has good inhibition to nonsmall-cell lung cancer, and safety is better than cyclophosphamide.And the Radix Stemonae and Flos Farfarae single medicinal material are without remarkable tumor-inhibiting action.
Embodiment 10 treats the oral Chinese medicine composition of pulmonary carcinoma to pharmacodynamic experiment in the body of small cell lung cancer
BALB/C nude mice, male and female half and half, 18 ~ 20g, 50.Small cell lung cancer cell strain NCI-H446 is inoculated at the PMRIl640 culture fluid 37 DEG C containing 10% calf serum at 5 % CO
2cell culture incubator in cultivate, take the logarithm growth mid-term NCI-H446 cell, be inoculated according to 1x10
7the dose inoculation of individual cell/nude mice sets up transitivity small cell lung cancer model in nude mice left hind.
Reach after 1cm until transplanted tumor average diameter and be divided into 5 groups at random, often organize 10 mices.A group as negative control group, feed standard mice full nutrition pellet; B group is administration group, and except normal feeding mice full nutrition pellet, evening every day, gavage gave granule prepared by embodiment 7, and dosage is 50mg/kg, successive administration 60 days; C group is positive controls lumbar injection cisplatin (0.5mg/kg), and evening every day is administered once, successive administration 60 days; D group is single medicinal material matched group, and except normal feeding mice full nutrition pellet, evening every day, gavage gave commercially available Stemona Root, and dosage is 50mg/kg, successive administration 60 days; E group is single medicinal material matched group, and except normal feeding mice full nutrition pellet, evening every day, gavage gave commercially available sea aster powder, and dosage is 50mg/kg, successive administration 60 days.Often group was in administration the 20th day, measured tumor volume, and calculate tumour inhibiting rate, computing formula is: (initial tumor volume-administration posterior tuberosity volume)/initial tumor volume (being expressed as a percentage).Often group calculates animal dis motility rate on the 60th day in administration.The results are shown in Table 1.
The tumour inhibiting rate of table 2 Chinese medicinal composition granules on small cell lung cancer mice and the impact of survival rate
A: representative has significant difference (p < 0.05) compared with C group; B: representative has the difference (p < 0.01) of highly significant compared with C group; C: representative has significant difference (p < 0.05) compared with A group; D: representative has the difference (p < 0.01) of highly significant compared with A group
From table 2, Chinese medicine composition oral liquid to the tumour inhibiting rate of small cell lung cancer mice lower than cisplatin, but compared with negative control group and single medicinal material matched group, still there is significant tumor-inhibiting action, and Chinese medicinal composition granules feeding mice is after 60 days, mouse survival rate is significantly higher than cisplatin group, prompting Chinese medicinal composition granules has certain inhibition to small cell lung cancer, and safety is better than cisplatin.
Claims (6)
1. treat an oral Chinese medicine composition for pulmonary carcinoma, it is characterized in that, the effective ingredient of this oral Chinese medicine composition is made up of the raw material of following weight ratio:
The processed with honey Radix Stemonae 20 weight portion
Radix Asteris (processed with honey) 40 weight portion
Raw Flos Farfarae 40 weight portion;
The preparation method of this oral Chinese medicine composition is as follows: ground by raw Flos Farfarae, cross 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2 ~ 4 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 5 ~ 8 times amount, and second time adds the decocting 1 ~ 3 hour of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 3 ~ 6 times amount; Collecting decoction, filter, filtrate being concentrated into relative density under 55 ~ 70 ° of C is the extractum of 1.20 ~ 1.30, mix homogeneously with above-mentioned powder, finally conveniently operation is directly or add pharmaceutically acceptable carrier and make arbitrary dosage form in the tablet of clinical acceptance, capsule, granule, oral liquid.
2. the preparation method of the oral Chinese medicine composition for the treatment of pulmonary carcinoma according to claim 1, is characterized in that, is ground by raw Flos Farfarae, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 6 times amount, and second time adds the soak by water 2 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 5 times amount; Collecting decoction, filters, and filtrate being concentrated into relative density under 65 ° of C is the extractum of 1.28; Mix homogeneously with above-mentioned powder, add the sodium carboxymethyl cellulose of extractum weight 0.5 times amount, the microcrystalline Cellulose of extractum weight 0.2 times amount, the lactose of extractum weight 0.5 times amount, mixing, 80% alcohol granulation, 45 ° of C are dried, after adding the magnesium stearate mixing of extractum weight 0.1 times amount, tabletting, obtains tablet.
3. the preparation method of the oral Chinese medicine composition for the treatment of pulmonary carcinoma according to claim 1, is characterized in that, is ground by raw Flos Farfarae, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 3.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 7 times amount, and second time adds the soak by water 1.5 hours of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight 4 times amount; Collecting decoction, filters, and filtrate being concentrated into relative density under 60 ° of C is the extractum of 1.24; Mix homogeneously with above-mentioned powder, dry, pulverize, cross 200 mesh sieves, add the Pulvis Talci of extractum weight 0.1 times amount, mix homogeneously, incapsulate and obtain capsule.
4. the preparation method of the oral Chinese medicine composition for the treatment of pulmonary carcinoma according to claim 1, is characterized in that, is ground by raw Flos Farfarae, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 2.2 hours of 5.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 2.5 hours of 5.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filters, and filtrate being concentrated into relative density under 65 ° of C is the extractum of 1.26; Mix homogeneously with above-mentioned powder, add the sweetener of extractum weight 2 times amount and the dextrin of extractum weight 0.01 times amount, spraying dry, be pressed into thin slice with the dry granulator that squeezes, more namely crushing and pelletizing obtains granule.
5. the preparation method of the oral Chinese medicine composition for the treatment of pulmonary carcinoma according to claim 1, is characterized in that, is ground by raw Flos Farfarae, crosses 100 mesh sieves for subsequent use; By the processed with honey Radix Stemonae and Radix Asteris (processed with honey) mixing, pulverize, decoct with water secondary, first time adds the soak by water 3 hours of 7.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight, and second time adds the soak by water 1.5 hours of 3.5 times amount of the processed with honey Radix Stemonae and Radix Asteris (processed with honey) gross weight; Collecting decoction, filters, and filtrate being concentrated into relative density under 65 ° of C is the extractum of 1.23; Mix homogeneously with above-mentioned powder, add distilled water diluting, add the Mel of extractum weight 0.1 ~ 0.5 times amount and the sucrose of extractum weight 0.5 ~ 1 times amount, boil, stirring and dissolving, filter while hot, antiseptic is added after cooling, add pH adjusting agent and pH value is adjusted to 4.2 ~ 6.3, use distilled water standardize solution, namely subpackage obtains oral liquid.
6. the preparation method of the oral Chinese medicine composition for the treatment of pulmonary carcinoma according to claim 5, is characterized in that, described antiseptic is sorbic acid, and described pH adjusting agent is citric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310112691.XA CN103142909B (en) | 2013-04-02 | 2013-04-02 | Orally traditional Chinese medicine composition for treating lung cancers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310112691.XA CN103142909B (en) | 2013-04-02 | 2013-04-02 | Orally traditional Chinese medicine composition for treating lung cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103142909A CN103142909A (en) | 2013-06-12 |
| CN103142909B true CN103142909B (en) | 2015-01-07 |
Family
ID=48541418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310112691.XA Expired - Fee Related CN103142909B (en) | 2013-04-02 | 2013-04-02 | Orally traditional Chinese medicine composition for treating lung cancers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142909B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105943945A (en) * | 2016-06-18 | 2016-09-21 | 冯原 | Traditional Chinese medicine composition for treating lung cancer, dripping pills and preparation method of dripping pills |
-
2013
- 2013-04-02 CN CN201310112691.XA patent/CN103142909B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 章永红教授治疗肺癌经验颉芳;洪祖剑;《吉林中医药》;20110630;第33卷(第6期);399-400页 * |
| 紫菀散药效物质基础的研究及新药研制;刘可越;《中国博士学位论文全文数据库》;20070630;第2007年卷(第06期);第12－13页 * |
| 蔡宝昌主编.紫菀、百部、款冬花.《中药炮制学》.中国中医药出版社,2008,210-213页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103142909A (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145158B (en) | Ginger and clove composition, preparation method of ginger and clove composition and use of ginger and clove composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN102166335A (en) | Ginger and long pepper composition as well as preparation method and application thereof in preparation of toxicity reducing and efficacy enhancing medicament in radiotherapy and chemotherapy of cancer | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| CN103446525B (en) | Treat dermopathic Chinese medicine composition and its preparation method and application | |
| CN102166260B (en) | Clove extract with tumor resisting effect and pharmaceutical preparation thereof | |
| CN102133385A (en) | Ginger and white pepper composition, preparation method thereof and application thereof to preparation of medicaments for attenuation and synergia in cancer radiochemotherapy | |
| CN102475698A (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN103142909B (en) | Orally traditional Chinese medicine composition for treating lung cancers | |
| CN103239636A (en) | Application of reed rhizome extract and gingerol in preparation of attenuated synergistic medicines for cancer chemotherapy | |
| CN102727867B (en) | Antineoplastic pharmaceutical composition and application thereof, kit and package | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof | |
| CN102018690B (en) | Anti-tumor medicament and application thereof | |
| CN107362158B (en) | Application of loganin aglycone in preparation of antitumor drugs | |
| CN109010495A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN102125646B (en) | Application of Chinese medicinal composition to treatment of stomach chronic inflammation with intestinal metaplasia and intraepithelial neoplasia | |
| CN102151275A (en) | Pancreatic cancer-resisting effect of oleanolic acid and pharmaceutical preparation of oleanolic acid | |
| CN102233055B (en) | Pharmaceutical composition used for treating cerebral stroke, and preparation method thereof | |
| CN102309487A (en) | The antihepatocarcinoma effect of piperine and pharmaceutical preparation thereof | |
| CN102114059A (en) | Nutmeg extract with antitumor effect and medicinal preparation thereof | |
| WO2015090139A1 (en) | Antitumor drug, preparation method and use thereof | |
| CN102151276A (en) | Pancreatic cancer resistance effect and pharmaceutical preparation of crataegolic acid | |
| CN101978992A (en) | Black pepper extract with anti-tumor effect and medicinal preparation thereof | |
| CN103142711B (en) | Anti-cancer pharmaceutical composition, and preparation method as well as application thereof | |
| CN102698255B (en) | Anti-tumor medicine composition and application, kit and package | |
| CN116492423A (en) | Traditional Chinese medicine composition for preventing and treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150107 Termination date: 20170402 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |